- $1.68bn
- $1.43bn
- $655.35m
Novocure gains as therapy succeeds in late-stage pancreatic cancer study
Brief: Novocure Announces Positive Topline Results From Phase 3 Panova-3 Clinical Trial Of Tumor Treating Fields Therapy For Pancreatic Cancer
Novocure's pancreatic cancer treatment meets main goal in late-stage study
Brief: FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
Novocure Ltd reports results for the quarter ended in September 30 - Earnings Summary
Brief: Novocure Q3 Revenue USD 155.095 Million Vs. IBES Estimate USD 143.9 Million
U.S. STOCKS ON THE MOVE-Wave Life Sciences, Dominion Energy, Voyager Therapeutics
U.S. STOCKS ON THE MOVE-United Airlines, Morgan Stanley, Autodesk
U.S. STOCKS ON THE MOVE-Gold miners, J.B. Hunt, Cisco Systems
Novocure jumps on FDA approval for lung cancer treatment
Brief: Novocure Ltd FDA Approves Optune Lua For Concurrent Use With Pd-1/Pd-L1 Inhibitors For Treatment Of Metastatic Non-Small Cell Lung Cancer
U.S. STOCKS ON THE MOVE-Dyne Therapeutics, Maxeon Solar, chip stocks
U.S. STOCKS ON THE MOVE-Walgreens, Copper miners, Simon Property
Novocure falls as CEO Asaf Danziger to step down
Brief: Novocure Announces Planned CEO Transition
Novocure Ltd reports results for the quarter ended in June - Earnings Summary
Brief: Novocure Q2 Revenue USD 150.356 Million Vs. IBES Estimate USD 135.8 Million
Novocure Ltd expected to post a loss of 41 cents a share - Earnings Preview
Brief: Tiger Study Reports New TTFields Therapy Survival Results For Newly Diagnosed Glioblastoma Patients In Germany